In vitro studies of the impact of maribavir on CMV-specific cellular immune responses

Journal of Clinical Virology

Volumn 75, Issue , 2016, Pages 53-59

  Stachel, Daniel ^a,b   Stevens Ayers, Terry ^a   Boeckh, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Ganciclovir; Maribavir; T cell responses

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; GANCICLOVIR; RIBONUCLEOSIDE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPETENCE; IMMUNOLOGIC TESTS; RIBONUCLEOSIDES;

EID: 84955463027     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.12.012     Document Type: Article

References (29)

1. Boeckh M., Bowden R.A., Gooley T., Myerson D., Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999, 93:1781-1782.
2. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
3. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
4. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J. Infect. Dis. 2002, 185:273-282.
5. Nakamae H., Storer B., Sandmaier B.M., Maloney D.G., Davis C., Corey L., Storb R., Boeckh M. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011, 96:1838-1845.
6. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46:2365-2372.
7. Heagy W., Crumpacker C., Lopez P.A., Finberg R.W. Inhibition of immune functions by antiviral drugs. J. Clin. Invest. 1991, 87:1916-1924.
8. Bowden R.A., Digel J., Reed E.C., Meyers J.D. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J. Infect. Dis. 1987, 156:899-903.
9. Battiwalla M., Wu Y., Bajwa R.P., Radovic M., Almyroudis N.G., Segal B.H., Wallace P.K., Nakamura R., Padmanabhan S., Hahn T., McCarthy P.L. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol. Blood Marrow Transplant. 2007, 13:765-770.
10. Sommadossi J.P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 1987, 31:452-454.
11. Cheng Y.C., Huang E.S., Lin J.C., Mar E.C., Pagano J.S., Dutschman G.E., Grill S.P. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy) methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:2767-2770.
12. Wang F.Z., Roy D., Gershburg E., Whitehurst C.B., Dittmer D.P., Pagano J.S. Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication. J. Virol. 2009, 83:12108-12117.
13. Wang L.H., Peck R.W., Yin Y., Allanson J., Wiggs R., Wire M.B. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 2003, 47:1334-1342.
14. Williams S.L., Hartline C.B., Kushner N.L., Harden E.A., Bidanset D.J., Drach J.C., Townsend L.B., Underwood M.R., Biron K.K., Kern E.R. In vitro activities of benzimidazole D- and l-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 2003, 47:2186-2192.
15. Winston D.J., Young J.A., Pullarkat V., Papanicolaou G.A., Vij R., Vance E., Alangaden G.J., Chemaly R.F., Petersen F., Chao N., Klein J., Sprague K., Villano S.A., Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
16. Avery R.K., Marty F.M., Strasfeld L., Lee I., Arrieta A., Chou S., Tatarowicz W., Villano S. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl. Infect. Dis. 2010, 12:489-496.
17. Drew W.L., Miner R.C., Marousek G.I., Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 2006, 37:124-127.
18. McSharry J.J., McDonough A., Olson B., Talarico C., Davis M., Biron K.K. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole l-riboside 1263W94. Clin. Diagn. Lab. Immunol. 2001, 8:1279-1281.
19. Chou S., Van Wechel L.C., Marousek G.I. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob. Agents Chemother. 2006, 50:2557-2559.
20. Chan J.H., Chamberlain S.D., Biron K.K., Davis M.G., Harvey R.J., Selleseth D.W., Dornsife R.E., Dark E.H., Frick L.W., Townsend L.B., Drach J.C., Koszalka G.W. Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94). Nucleosides Nucleotides Nucleic Acids 2000, 19:101-123.
21. Marty F.M., Ljungman P., Papanicolaou G.A., Winston D.J., Chemaly R.F., Strasfeld L., Young J.A., Rodriguez T., Maertens J., Schmitt M., Einsele H., Ferrant A., Lipton J.H., Villano S.A., Chen H., Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 2011, 11:284-292.
22. Winston D.J., Saliba F., Blumberg E., Abouljoud M., Garcia-Diaz J.B., Goss J.A., Clough L., Avery R., Limaye A.P., Ericzon B.G., Navasa M., Troisi R.I., Chen H., Villano S.A., Uknis M.E. Efficacy and safety of maribavir dosed at 100mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 2012, 12:3021-3030.
23. Maris M., Boeckh M., Storer B., Dawson M., White K., Keng M., Sandmaier B., Maloney D., Storb R., Storek J. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp. Hematol. 2003, 31:941-952.
24. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., Stevens-Ayers T., Flowers M.E., Cunningham T., Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
25. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
26. Pollack M., Heugel J., Xie H., Leisenring W., Storek J., Young J.A., Kukreja M., Gress R., Tomblyn M., Boeckh M. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 2011, 17:664-673.
27. I.Viropharma, Investigator's brochure Maribavir Tablets, 2006 p. Tables 5 and 6.
28. Ma J.D., Nafziger A.N., Villano S.A., Gaedigk A., Bertino J.S. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 2006, 50:1130-1135.
29. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., Drew W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 2002, 46:2969-2976.